Status:

UNKNOWN

Continuous Alcohol Monitoring for Pancreatitis

Lead Sponsor:

Cedars-Sinai Medical Center

Conditions:

Pancreatitis

Alcohol Drinking

Eligibility:

All Genders

18-75 years

Brief Summary

The purpose the research is to demonstrate the feasibility of using a transdermal alcohol sensing device (BACtrack Skyn), and to correlate biological and self-reported alcohol measures with the transd...

Detailed Description

Alcohol is the leading cause of recurrent acute and chronic pancreatitis, which greatly elevates the risk of pancreatic cancer. Reducing alcohol intake in patients with a history of alcoholic pancreat...

Eligibility Criteria

Inclusion

  • Aged 18-75 years at the time of eligibility assessment
  • History of at least one AP per Revised Atlanta Classification (20) within past 3 years from screening, which requires two of the following evidence of pancreatitis:
  • Abdominal pain consistent with AP (acute onset of a persistent, severe, epigastric pain often radiating to the back)
  • Serum lipase activity (or amylase activity) at least three times greater than the upper limit of normal
  • Characteristic findings of AP on contrast-enhanced computed tomography (CECT), magnetic resonance imaging (MRI) or transabdominal ultrasonography
  • Access to a mobile or portable device that has the capability to sync to the BACtrack sensor and internet connection for syncing purposes.

Exclusion

  • Pancreatitis presumed to be related to: gallstones, medication, trauma, autoimmune pancreatitis, post-ERCP pancreatitis, pancreatic ductal adenocarcinoma, suspected cystic neoplasm, neuroendocrine tumors, and other uncommon tumors.
  • Episode of acute pancreatitis requiring hospitalization in the past 4 weeks.
  • Current medical or psychiatric illnesses that in the investigator's opinion would compromise their ability to tolerate study procedures.
  • Currently incarcerated.
  • Known pregnancy.

Key Trial Info

Start Date :

June 1 2020

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

June 1 2021

Estimated Enrollment :

16 Patients enrolled

Trial Details

Trial ID

NCT04350996

Start Date

June 1 2020

End Date

June 1 2021

Last Update

April 29 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cedars-Sinai Medical Center

Los Angeles, California, United States, 90048